Vanguard Group Inc. Grows Stock Holdings in GoodRx Holdings, Inc. $GDRX

Key Points

• Vanguard Group Inc. increased its stake in GoodRx Holdings by 3.0%, owning approximately 8.6 million shares worth around $38 million.
• GoodRx reported a Q2 EPS of $0.09, falling slightly short of analyst expectations, and revenue of $203.07 million, which was also below projections.
• 5 analysts rate GoodRx with a Buy and 6 give it a Hold, reflecting a consensus target price of $5.80 per share.

Vanguard Group Inc. boosted its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 3.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,624,872 shares of the company's stock after buying an additional 251,833 shares during the quarter. Vanguard Group Inc. owned approximately 2.25% of GoodRx worth $38,036,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GDRX. LPL Financial LLC lifted its holdings in GoodRx by 93.9% during the 4th quarter. LPL Financial LLC now owns 46,320 shares of the company's stock valued at $215,000 after buying an additional 22,436 shares in the last quarter. Envestnet Asset Management Inc. bought a new stake in GoodRx during the 4th quarter valued at about $84,000. Raymond James Financial Inc. bought a new stake in GoodRx during the 4th quarter valued at about $2,500,000. Barclays PLC lifted its holdings in GoodRx by 18.4% during the 4th quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after buying an additional 25,815 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in GoodRx by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock valued at $9,264,000 after buying an additional 369,553 shares in the last quarter. Institutional investors own 63.77% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. The Goldman Sachs Group decreased their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Finally, UBS Group reduced their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $5.80.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.53% of the company's stock.

GoodRx Stock Down 0.2%

Shares of NASDAQ:GDRX traded down $0.01 during trading hours on Monday, hitting $4.35. The company's stock had a trading volume of 1,569,793 shares, compared to its average volume of 6,098,105. The firm's fifty day moving average price is $4.57 and its 200 day moving average price is $4.48. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx Holdings, Inc. has a 52 week low of $3.31 and a 52 week high of $8.38. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of 43.50, a P/E/G ratio of 1.90 and a beta of 1.23.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The firm had revenue of $203.07 million during the quarter, compared to analysts' expectations of $205.72 million. During the same period in the previous year, the firm earned $0.08 EPS. The firm's quarterly revenue was up 1.2% on a year-over-year basis. As a group, research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.